Pourabdollah Toutkaboni Mihan, Askari Elham, Heshmatnia Jalal, Rezaei Mitra, Hasanzad Maryam, Dorudinia Atosa, Bakhshayesh Karam Mehrdad, Mohammadi Ziazi Leila, Sheikholeslami Maryam-Fatemeh
Pediatric Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Disease (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Chronic Respiratory Diseases Research Center, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Tanaffos. 2024 Jan;23(1):65-72.
Recently, genetic mutations in surfactant protein C (SFTPC) have been linked to diffuse parenchymal lung diseases (DPLD). The present study investigated mutations among Iranian patients with DPLD for the first time.
In this study, we examined 28 patients diagnosed with DPLD. Patients were divided into two groups: 23 cases (82.1%) had interstitial lung disease (ILD), 7 (30.4%) of which were categorized as familial ILD, and 5 cases (17.9%) had pulmonary alveolar proteinosis (PAP). Genetic variations in the gene were detected by direct DNA sequencing.
The mean (±SD) age of patients was 21.8 (± 17.1) years and 60.7% of the patients were male. Overall, 11 different mutations were detected in the gene. Two novel mutations, c.202-43 G>A and c.416 G>C, were detected among patients. The c.201+49 C>T mutation showed a significant difference with the minor allele frequency (MAF) data. There was no significant difference between the most frequent mutations in Iranian patients and those of the general population in the world. The proximity analysis showed similarity between Iranian patients and patients of the African race. We did not find any correlation between mutations and DPLD in the patients.
It seems that the rs2070684 (c.201+49 C>T) mutation could be used as a specific genetic marker for distinguishing the Iranian population from other human races in the world. There was a correlation between some intronic variations and the development of disease. A new missense mutation, c.416 G>C that encodes Arg139Thr, could probably damage the protein structure and/or function and cause the signs and symptoms of DPLD.
最近,表面活性蛋白C(SFTPC)基因突变与弥漫性肺实质疾病(DPLD)有关。本研究首次调查了伊朗DPLD患者中的基因突变情况。
在本研究中,我们检查了28例诊断为DPLD的患者。患者分为两组:23例(82.1%)患有间质性肺病(ILD),其中7例(30.4%)被归类为家族性ILD,5例(17.9%)患有肺泡蛋白沉积症(PAP)。通过直接DNA测序检测该基因的遗传变异。
患者的平均(±标准差)年龄为21.8(±17.1)岁,60.7%的患者为男性。总体而言,在该基因中检测到11种不同的突变。在患者中检测到两种新的突变,即c.202-43 G>A和c.416 G>C。c.201+49 C>T突变与次要等位基因频率(MAF)数据存在显著差异。伊朗患者中最常见的突变与世界普通人群的突变之间没有显著差异。亲缘关系分析显示伊朗患者与非洲种族患者相似。我们在患者中未发现该基因突变与DPLD之间存在任何相关性。
似乎rs2070684(c.201+49 C>T)突变可作为区分伊朗人群与世界其他人类种族的特定遗传标记。一些内含子变异与疾病发展之间存在相关性。一种新的错义突变c.416 G>C,编码Arg139Thr,可能会破坏蛋白质结构和/或功能,并导致DPLD的体征和症状。